Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05112237 · ClinicalTrials.gov registry record
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
A clinical trial of Cardiomyopathy, sponsored by Tenaya Therapeutics.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT05112237 is a study of Cardiomyopathy that is actively recruiting participants, run by Tenaya Therapeutics. The registered enrollment target is 200 participants, below the 549-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05112237, a study of Cardiomyopathy, is actively recruiting participants, sponsored by Tenaya Therapeutics.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Conditions Studied
Study Locations (20)
New York
- Cohen Children's Medical Center - Lake Success
- Mount Sinai - New York
- Columbia University Irving Medical Center - New York
- Montefiore Medical Center, Albert Einstein College of Medicine - The Bronx
California
- Children's Hospital Los Angeles - Los Angeles
- University of California Davis Health - Sacramento
- Rady Children's Hospital - San Diego - San Diego
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic Main Campus - Cleveland
- DDC Clinic Center for Special Needs Children - Middlefield
Pennsylvania
- Cardiology Care for Children - Lancaster
- Children's Hospital of Philadelphia - Philadelphia
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh - Pittsburgh
Missouri
- Children's Mercy Hospital Kansas - Kansas City
- St. Louis Children's Hospital - St Louis
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- University of Colorado Hospital - Anschutz Medical Campus - Aurora
Delaware
- Nemours Alfred I. Dupont Hospital for Children - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05112237
The ClinicalTrials.gov registry entry for NCT05112237 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 549-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (64% lower). The listed sponsor is Tenaya Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT05112237 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New York, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT05112237 about?
NCT05112237 is a clinical study titled "Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy". The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, p...
What is the current status of trial NCT05112237?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2021-11-01. Estimated completion is 2028-06.
What conditions does trial NCT05112237 study?
This clinical trial studies the following conditions: Cardiomyopathy.
Who is sponsoring clinical trial NCT05112237?
This trial is sponsored by Tenaya Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05112237 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Molecular Imaging of Primary Amyloid Cardiomyopathy
RECRUITING · NA
-
Impella Reverse Remodeling in End-Stage Heart Failure
RECRUITING
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.